VIDO-InterVac team tackles coronavirus: Researchers developing prototype vaccines at USask
VIDO-InterVac researchers have successfully grown the virus in a cell culture and are now testing a new vaccine in animals as part of the global effort to combat the coronavirus threat.
The Government of Canada announced funding for the University of Saskatchewan’s Vaccine and Infectious Disease Organization – International Vaccine Centre (VIDO-InterVac), one of the largest and most advanced infectious disease research facilities in the world. With $11 million in funding from the Canada Foundation for Innovation, VIDO-InterVac will be able to strengthen its existing expertise in coronavirus research and to help develop a vaccine for COVID-19. An additional $12 million from Western Economic Diversification’s Regional Economic Growth Through Innovation program will help VIDO-InterVac expand its bio-manufacturing capacity to support clinical trials.